
Accelerating BRPF1b hit identification with BioPhysical and Active Learning Screening (*BioPALS*)


Sandeep Pal, $^{\#[a]}$ Zandile Nare, $^{\#[a]}$ Vincenzo A. Rao, $^{[a]}$ Brian O. Smith, $^{[b]}$ Ian Morrison, $^{[a]}$ Edward A. Fitzgerald, $^{[c]}$ Andrew Scott, $^{[a]}$ Matilda J. Bingham $^{[a]}$ and Thomas Pesnot* $^{[a]}$

[a] Concept Life Sciences Ltd, Frith Knoll Road, Chapel-en-le-Frith, High Peak, SK23 0PG, United Kingdom, [b] School of Molecular Biosciences, College of Medical Veterinary and Life Sciences, University of Glasgow G12 8QQ, United Kingdom, [c] Creoptix AG, Zugerstrasse 76, CH–8820 Wädenswil, Switzerland

Supplementary Information





Supplementary Figure 1: Chemical structure of the 27 known BRPF1b inhibitors used for the similarity search.




Supplementary Figure 2: Representative waveRAPID® sensorgram for GSK6853 binding to BRPF1a with indicated kinetic and fitting parameters.


_





Supplementary Figure 3: LCMS purity of **compound 2**.






Supplementary Figure 4: LCMS purity of **compound 3**.


8

0.82


0.30


6344.9






Supplementary Figure 5: LCMS purity of **compound 4**.






Supplementary Figure 6: LCMS purity of compound 5.

1.146e+2 Range: 1.149e+2





Supplementary Figure 7: LCMS purity of **compound 7**.

		GCI (wave	RAPID®)		ITC					DSF
Isoform	Com-	K_{D}	k _a	k_{d}	K_{D}	ΔΗ	ΔG	-T∆S	N	ΔT_{m}
	pound	(nM)	(M/s^{-1})	(s-1)	(nM)	(kcal.mol ⁻¹)	(kcal.mol ⁻¹)	(kcal.mol ⁻¹)		(°C)
BRPF1a	GSK6853	2.7×10^{3}	1.3 × 10 ⁶	3.61	n.d.	n.d.	n.d.	n.d.	n.d.	+1.0
	NI-57	2.7× 10 ⁴	1.2×10^{5}	3.2	n.d.	n.d.	n.d.	n.d.	n.d.	+0.7
BRPF1b	GSK6853	7.8	1.3 × 10 ⁶	1.0 × 10 ⁻²	15	-16.2	-10.7	5.5	0.9	+19.9
	NI-57	8.6	1.9×10^{7}	1.6×10^{-1}	36	-7.4	-10.2	-2.7	1.3	+ 17

Supplementary Table 1: Comparison of GSK6853 and NI-57 binding to BRPF1a and BPRF1b.